JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Development and validation of a nomogram to predict the survival and estimate surgical benefits for gastric cancer with liver metastasis receiving primary tumor resection

  • 0Digestive Diseases Center, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, China.
Frontiers in Oncology +

|

November 25, 2024

|

November 25, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

This study developed a nomogram to predict survival for gastric cancer with liver metastasis (GCLM) patients undergoing primary tumor resection (PTR). While PTR improved overall survival, high-risk GCLM patients did not benefit from PTR, aiding clinical decision-making.

Area Of Science

  • Oncology
  • Surgical Gastroenterology
  • Biostatistics

Background

  • Surgical treatment for gastric cancer with liver metastasis (GCLM) remains controversial.
  • Predicting survival and surgical benefits for GCLM patients is crucial for treatment planning.

Purpose Of The Study

  • To develop and validate a nomogram for predicting survival in GCLM patients.
  • To estimate the benefits of primary tumor resection (PTR) for GCLM patients.

Main Methods

  • Utilized data from 616 GCLM patients from the SEER database and 74 from a Chinese center.
  • Developed a nomogram based on independent risk factors identified through Cox regression analysis.
  • Validated the nomogram using an external dataset and compared survival outcomes with and without PTR.

Main Results

  • Patients undergoing PTR showed longer survival than those without PTR in the SEER cohort (p<0.0001).
  • Key predictors for survival in GCLM patients with PTR included T stage, differentiation grade, non-hepatic metastases, and adjuvant therapy.
  • A nomogram was established, but high-risk GCLM patients (n=255) identified by the nomogram did not benefit from PTR compared to non-operative patients (n=123) (p=0.25).

Conclusions

  • The developed nomogram accurately predicts survival for GCLM patients undergoing PTR.
  • While PTR benefits the overall GCLM population, it does not improve outcomes for high-risk subgroups.
  • The nomogram can assist clinicians in making informed treatment decisions for GCLM patients.

Keywords: